118 related articles for article (PubMed ID: 21671835)
21. Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.
Nabhan C; Patel A; Villines D; Tolzien K; Kelby SK; Lestingi TM
Clin Genitourin Cancer; 2014 Feb; 12(1):27-32. PubMed ID: 24238760
[TBL] [Abstract][Full Text] [Related]
22. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer.
Italiano A; Ortholan C; Oudard S; Pouessel D; Gravis G; Beuzeboc P; Bompas E; Fléchon A; Joly F; Ferrero JM; Fizazi K
Eur Urol; 2009 Jun; 55(6):1368-75. PubMed ID: 18706755
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.
Buonerba C; Federico P; D'Aniello C; Rescigno P; Cavaliere C; Puglia L; Ferro M; Altieri V; Perdonà S; De Placido S; Di Lorenzo G
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1455-61. PubMed ID: 21365219
[TBL] [Abstract][Full Text] [Related]
24. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Hensley ML; Sill MW; Scribner DR; Brown J; Debernardo RL; Hartenbach EM; McCourt CK; Bosscher JR; Gehrig PA
Gynecol Oncol; 2009 Dec; 115(3):460-5. PubMed ID: 19811811
[TBL] [Abstract][Full Text] [Related]
25. [Experience with sunitinib in hormone-resistant metastatic prostate cancer that is unresponsive to docetaxel].
Gasent JM; Grande E; Casinello J; Provencia M; Laforga JB; Alberola V
Actas Urol Esp; 2011 Jan; 35(1):57-60. PubMed ID: 21256396
[TBL] [Abstract][Full Text] [Related]
26. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
27. Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel.
Gebbia V; Serretta V; Borsellino N; Valerio MR;
Urology; 2011 Nov; 78(5):1125-30. PubMed ID: 22054386
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
Schneider BJ; Gadgeel SM; Ramnath N; Wozniak AJ; Dy GK; Daignault S; Kalemkerian GP
J Thorac Oncol; 2011 Jun; 6(6):1117-20. PubMed ID: 21512407
[TBL] [Abstract][Full Text] [Related]
29. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
[TBL] [Abstract][Full Text] [Related]
30. An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer.
Pezaro C; Rosenthal MA; Gurney H; Davis ID; Underhill C; Boyer MJ; Kotasek D; Solomon B; Toner GC
Am J Clin Oncol; 2009 Aug; 32(4):338-41. PubMed ID: 19363437
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study.
Kentepozidis N; Soultati A; Giassas S; Vardakis N; Kalykaki A; Kotsakis A; Papadimitraki E; Pantazopoulos N; Bozionellou V; Georgoulias V
Cancer Chemother Pharmacol; 2012 Jul; 70(1):161-8. PubMed ID: 22660737
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
Li XS; Wu X; Zhao PJ; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; Wang G; He ZS; Zhou LQ; Jin J
Chin Med J (Engl); 2011 Sep; 124(18):2920-4. PubMed ID: 22040503
[TBL] [Abstract][Full Text] [Related]
33. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
[TBL] [Abstract][Full Text] [Related]
34. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
Wetmore C; Daryani VM; Billups CA; Boyett JM; Leary S; Tanos R; Goldsmith KC; Stewart CF; Blaney SM; Gajjar A
Cancer Med; 2016 Jul; 5(7):1416-24. PubMed ID: 27109549
[TBL] [Abstract][Full Text] [Related]
35. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
[TBL] [Abstract][Full Text] [Related]
36. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
George S; Blay JY; Casali PG; Le Cesne A; Stephenson P; Deprimo SE; Harmon CS; Law CN; Morgan JA; Ray-Coquard I; Tassell V; Cohen DP; Demetri GD
Eur J Cancer; 2009 Jul; 45(11):1959-68. PubMed ID: 19282169
[TBL] [Abstract][Full Text] [Related]
37. A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies.
Wuthrick EJ; Kamrava M; Curran WJ; Werner-Wasik M; Camphausen KA; Hyslop T; Axelrod R; Andrews DW; Glass J; Machtay M; Dicker AP
Cancer; 2011 Dec; 117(24):5548-59. PubMed ID: 21647871
[TBL] [Abstract][Full Text] [Related]
38. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.
Boehmer A; Anastasiadis AG; Feyerabend S; Nagele U; Kuczyk M; Schilling D; Corvin S; Merseburger AS; Stenzl A
Anticancer Res; 2005; 25(6C):4481-6. PubMed ID: 16334130
[TBL] [Abstract][Full Text] [Related]
39. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer.
Fountzilas G; Fragkoulidi A; Kalogera-Fountzila A; Nikolaidou M; Bobos M; Calderaro J; Andreiuolo F; Marselos M
Cancer Chemother Pharmacol; 2010 Mar; 65(4):649-60. PubMed ID: 19655144
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.
Whang YE; Armstrong AJ; Rathmell WK; Godley PA; Kim WY; Pruthi RS; Wallen EM; Crane JM; Moore DT; Grigson G; Morris K; Watkins CP; George DJ
Urol Oncol; 2013 Jan; 31(1):82-6. PubMed ID: 21396844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
